Last reviewed · How we verify
NCT06828341
A Single-arm, Open, Exploratory Clinical Study of Allogeneic CAR-T Cells in the Treatment of Relapsed/Refractory Brain Gliomas With Positive CD70 Expression
EARLY_PHASE1 trial testing CAR-T in Gliomas in 3 participants. Currently enrolling.
6 July 2024
Quick facts
| Lead sponsor | JIANG LONGWEI |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 3 |
| Start date | 13 June 2024 |
| Primary completion | 6 July 2024 |
| Estimated completion | 30 June 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- CAR-T — full drug profile →
Conditions studied
- Gliomas — all drugs for Gliomas →
Sponsor
JIANG LONGWEI — full company profile →
Who can join
18 and older, any sex, with Gliomas. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to learn if allogeneic CAR-T cells can treat patients with advanced gliomas. The main questions it aims to answer are: Evaluate the safety of allogeneic CAR-T cells in the treatment of advanced gliomas. To evaluate the effectiveness of allogeneic CAR-T cells in the treatment of advanced gliomas and to study its immunological properties in patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Targeting immune microenvironment-mediated mesenchymal transition in glioblastoma: Molecular mechanisms and translational strategies.
Liu F, Chen J, Yu M, Liu Y, et al · · 2026 · PMID 42170360 · DOI 10.1093/noajnl/vdag075
Verify or expand the search:
- PubMed search for NCT06828341
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CAR-T
Trials testing the same drug.
- NCT07370064 — Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia · Phase 1, PHASE2 · not yet recruiting
- NCT07338357 — Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML · EARLY_PHASE1 · not yet recruiting
- NCT07441291 — CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT · Phase 3 · recruiting
- NCT07152210 — Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced C · NA · recruiting
- NCT07152236 — Clinical Study on the Safety and Efficacy of B7H3 CAR T Cells in Patients With B7H3 Positive Solid Tumors · NA · recruiting
Other recruiting trials for Gliomas
Currently open trials in the same condition.
- NCT07374692 — Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors · NA · recruiting
- NCT07198256 — AI-assisted Diagnosis of Malignant Brain Tumors · recruiting
- NCT05804227 — Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas · EARLY_PHASE1 · recruiting
- NCT06736470 — Surgical Suction Aspirates Fluorescence Measurement · recruiting
Other JIANG LONGWEI trials
Trials by the same sponsor.
- NCT07343791 — Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Tr · EARLY_PHASE1 · recruiting
- NCT06496724 — A Clinical Study of Albumin-bound Paclitaxel/Granulocyte-based Therapy for Recurrent/Metastatic Breast Cancer · NA · recruiting
- NCT06431529 — A Study of Tumor Neoantigen-specific T Cells in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06828341 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by JIANG LONGWEI
- Last refreshed: 14 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06828341.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing